Novartis has made kidney disorders an area of focus, and it’s now adding a new drug prospect through a deal to acquire Regulus Therapeutics, a biotech with a drug ready for pivotal testing in a ...

Novartis (NYSE:NVS) has agreed to acquire biopharmaceutical firm Regulus Therapeutics (NASDAQ:RGLS) for an initial payment of $7.00 a share in cash at closing, or $0.8B. The upfront cash portion ...

Novartis is set to buy U.S. biotech Regulus Therapeutics for up to $1.7 billion in a move to boost its renal-disease pipeline. The Swiss pharma giant said Wednesday that it would pay Regulus ...

Novartis has agreed to acquire Regulus Therapeutics for a total equity value of up to roughly $1.7 billion. With the merger, the Swiss pharmaceutical company aims to bring to more patients ...

Novartis NOVN0.71%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS-0.38%decrease; red down pointing triangle for a total equity value of up to roughly $1.7 ...

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company ...

You can reach Jason on Signal at JasonMast.05. Novartis said Wednesday it would buy Regulus Therapeutics and its experimental kidney drug for $800 million upfront. The immediate payout is more ...

April 30 (Reuters) - Novartis (NOVN.S), opens new tab has agreed to buy Regulus Therapeutics (RGLS.O), opens new tab for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...